2,103 reports of this reaction
2.1% of all VENETOCLAX reports
#11 most reported adverse reaction
WHITE BLOOD CELL COUNT DECREASED is the #11 most commonly reported adverse reaction for VENETOCLAX, manufactured by AbbVie Inc.. There are 2,103 FDA adverse event reports linking VENETOCLAX to WHITE BLOOD CELL COUNT DECREASED. This represents approximately 2.1% of all 98,823 adverse event reports for this drug.
VENETOCLAX has an overall safety score of 88 out of 100. Patients taking VENETOCLAX who experience white blood cell count decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WHITE BLOOD CELL COUNT DECREASED is a less commonly reported adverse event for VENETOCLAX, but still significant enough to appear in the safety profile.
In addition to white blood cell count decreased, the following adverse reactions have been reported for VENETOCLAX:
The following drugs have also been linked to white blood cell count decreased in FDA adverse event reports:
WHITE BLOOD CELL COUNT DECREASED has been reported as an adverse event in 2,103 FDA reports for VENETOCLAX. This does not prove causation, but indicates an association observed in post-market surveillance data.
WHITE BLOOD CELL COUNT DECREASED accounts for approximately 2.1% of all adverse event reports for VENETOCLAX, making it a notable side effect.
If you experience white blood cell count decreased while taking VENETOCLAX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.